Tenet Healthcare Corporation — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. Amounts are in millions except per-share data. Tenet operates Hospital Operations, Ambulatory Care (USPI), and Conifer, its revenue-cycle and related services business.
Key financial results
| Metric | Q2 2023 | Q2 2022 | First half 2023 | First half 2022 |
|---|---|---|---|---|
| Net operating revenues | $5,082 | $4,638 | $10,103 | $9,383 |
| Operating income | $604 | $553 | $1,207 | $1,201 |
| Net income | $293 | $179 | $589 | $459 |
| Net income attributable to Tenet common shareholders | $123 | $38 | $266 | $178 |
| Diluted EPS | $1.15 | $0.35 | $2.47 | $1.64 |
| Adjusted EBITDA (non-GAAP) | $843 | $843 | $1,675 | $1,731 |
| Adjusted EBITDA margin | 16.6% | 18.2% | 16.6% | 18.4% |
- Q2 revenue grew 9.6%; operating income margin was 11.9%, flat year over year. First-half revenue grew 7.7%, while operating income was nearly flat and operating margin declined to 11.9% from 12.8%.
- Q2 Hospital Operations revenue before inter-segment eliminations rose 7.6%; Ambulatory Care rose 22.2%, driven by acquisitions, more cases, and higher revenue per case; Conifer revenue fell 3.0%. First-half Adjusted EBITDA fell 3.2%; segment figures were Hospital Operations $793 (down from $945), Ambulatory Care $710 (up from $601), and Conifer $172 (down from $185).
- Operating costs increased: first-half salaries, wages and benefits were $4,543, supplies $1,782, and other operating expenses $2,218. Management cited inflation, higher volumes, and notably higher malpractice expense; contract labor expense declined as recruitment improved.
- Cash and cash equivalents were $934 at June 30, versus $858 at year-end. First-half operating cash flow was $1,047, investing cash use $467, and financing cash use $504. Operating cash flow was up from $347 in the prior-year period, principally because 2022 included $475 of Medicare advance repayments or recoupments.
- Capital expenditures were $367 in the first half. Management expects full-year 2023 continuing-operations capital expenditures of approximately $675–$725, including amounts accrued at year-end.
- Long-term debt, net of current portion, was $14,907; total long-term debt including current maturities was $15,048. Net debt to trailing-12-month Adjusted EBITDA was 4.14x. Tenet had $934 cash and $1,500 available under its revolving credit facility, with no revolver borrowings, and reported compliance with its credit-facility covenants.
- In May 2023, Tenet issued $1,350 of 6.750% first-lien notes due 2031 and used proceeds plus cash to redeem $1,345 principal of 4.625% notes due in 2024. The refinancing extended maturities but increased the coupon; Tenet recorded an $11 early-extinguishment loss.
Changes, outlook, risks, and unusual items
- Hospital volumes improved: Q2 same-hospital adjusted admissions increased 3.2%; consolidated ambulatory cases increased 9.1%. Tenet attributed hospital revenue growth partly to higher volumes, commercial rate increases, the new Fort Mill hospital, and comparison with the 2022 cybersecurity disruption.
- COVID-19 grant income fell sharply: $8 in Q2 2023 versus $94 in Q2 2022; first-half amounts were $11 versus $100. The public health emergency ended May 11, 2023, and the company does not expect significant future COVID-related funding.
- Management’s stated priorities include growing ambulatory care, improving hospital efficiency, refining its facility portfolio, and reducing leverage over time. No full-year earnings or Adjusted EBITDA guidance is provided in the filing text.
- Management estimated proposed Medicare payment changes could increase annual Medicare inpatient fee-for-service payments by about $59; proposed outpatient changes could add about $23 for acute-care hospitals and $17 for USPI facilities. These are estimates based on proposed rules, not finalized guidance. A proposed 340B-related adjustment was estimated to reduce annual hospital and surgical-hospital revenue by less than $10; the proposed physician-fee-schedule rule was estimated to reduce fee-for-service revenue by less than $6.
- Key operating and financial risks include staffing shortages and wage inflation, supply-chain and construction delays, payer negotiations and reimbursement changes, Medicaid eligibility redeterminations, patient receivable collectability, malpractice costs, litigation and government investigations, and potential future asset impairments. Tenet noted managed-care payer concentration: its top 10 payers generated 65% of first-half managed-care patient-service revenue.
- Tenet settled a Department of Justice investigation concerning Detroit Medical Center in May 2023 and paid the settlement during Q2; the settlement amount is not clearly stated in the filing text, and Tenet said it had fully reserved for it. The company also received $31 of insurance recoveries tied to its 2022 cybersecurity incident in the first half, including $27 recorded as net operating revenue.
- Tenet classified its 51% interest in San Ramon Regional Medical Center and related operations as held for sale; closing was expected in 2023, subject to regulatory review and customary conditions. The company repurchased $90 of shares in the first half under its $1 billion authorization.
Important facts for investors to verify
- Whether hospital cost growth, especially malpractice and other operating expenses, moderates relative to revenue and volume growth.
- Whether Ambulatory Care acquisition-driven growth converts into sustained segment earnings and cash generation.
- Progress on leverage reduction, refinancing costs, and cash available after capital expenditures, distributions, acquisitions, and share repurchases.
- Final Medicare and Medicaid rule outcomes, payer contract developments, and any effect of Medicaid redeterminations on payer mix and collections.
- Developments in legal matters, the San Ramon sale, and any further costs or recoveries related to the cybersecurity incident.